- Home
- FNWB vs ANL Comparison
FNWB vs ANL Comparison
Compare FNWB & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNWB
- ANL
- Stock Information
- Founded
- FNWB 1923
- ANL 2004
- Country
- FNWB United States
- ANL Cayman Islands
- Employees
- FNWB N/A
- ANL N/A
- Industry
- FNWB Banks
- ANL
- Sector
- FNWB Finance
- ANL
- Exchange
- FNWB Nasdaq
- ANL Nasdaq
- Market Cap
- FNWB 69.0M
- ANL 61.8M
- IPO Year
- FNWB 2015
- ANL 2023
- Fundamental
- Price
- FNWB $7.84
- ANL $1.60
- Analyst Decision
- FNWB Hold
- ANL Hold
- Analyst Count
- FNWB 1
- ANL 1
- Target Price
- FNWB $12.00
- ANL N/A
- AVG Volume (30 Days)
- FNWB 24.4K
- ANL 11.2K
- Earning Date
- FNWB 10-28-2025
- ANL 10-24-2025
- Dividend Yield
- FNWB 3.56%
- ANL N/A
- EPS Growth
- FNWB N/A
- ANL N/A
- EPS
- FNWB N/A
- ANL N/A
- Revenue
- FNWB $48,874,000.00
- ANL N/A
- Revenue This Year
- FNWB $34.16
- ANL N/A
- Revenue Next Year
- FNWB $11.73
- ANL N/A
- P/E Ratio
- FNWB N/A
- ANL N/A
- Revenue Growth
- FNWB N/A
- ANL N/A
- 52 Week Low
- FNWB $6.05
- ANL $1.10
- 52 Week High
- FNWB $12.10
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- FNWB 55.60
- ANL 38.39
- Support Level
- FNWB $7.76
- ANL $1.56
- Resistance Level
- FNWB $8.10
- ANL $1.80
- Average True Range (ATR)
- FNWB 0.22
- ANL 0.09
- MACD
- FNWB 0.04
- ANL -0.02
- Stochastic Oscillator
- FNWB 51.28
- ANL 10.44
About FNWB First Northwest Bancorp
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.